We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Elimination of tumor hypoxia by eribulin demonstrated by <sup>18</sup>F-FMISO hypoxia imaging in human tumor xenograft models.
- Authors
Zhao, Songji; Yu, Wenwen; Ukon, Naoyuki; Tan, Chengbo; Nishijima, Ken-ichi; Shimizu, Yoichi; Higashikawa, Kei; Shiga, Tohru; Yamashita, Hiroko; Tamaki, Nagara; Kuge, Yuji
- Abstract
Background: Eribulin, an inhibitor of microtubule dynamics, shows antitumor potency against a variety of solid cancers through its antivascular activity and remodeling of tumor vasculature. 18F-Fluoromisonidazole (18F-FMISO) is the most widely used PET probe for imaging tumor hypoxia. In this study, we utilized 18F-FMISO to clarify the effects of eribulin on the tumor hypoxic condition in comparison with histological findings. Material and methods: Mice bearing a human cancer cell xenograft were intraperitoneally administered a single dose of eribulin (0.3 or 1.0 mg/kg) or saline. Three days after the treatment, mice were injected with 18F-FMISO and pimonidazole (hypoxia marker for immunohistochemistry), and intertumoral 18F-FMISO accumulation levels and histological characteristics were determined. PET/CT was performed pre- and post-treatment with eribulin (0.3 mg/kg, i.p.). Results: The 18F-FMISO accumulation levels and percent pimonidazole-positive hypoxic area were significantly lower, whereas the number of microvessels was higher in the tumors treated with eribulin. The PET/CT confirmed that 18F-FMISO distribution in the tumor was decreased after the eribulin treatment. Conclusions: Using 18F-FMISO, we demonstrated the elimination of the tumor hypoxic condition by eribulin treatment, concomitantly with the increase in microvessel density. These findings indicate that PET imaging using 18F-FMISO may provide the possibility to detect the early treatment response in clinical patients undergoing eribulin treatment.
- Subjects
ERIBULIN; NITROIMIDAZOLES; HYPOXEMIA; THERAPEUTICS; TUMORS; CANCER cells; BLOOD vessels
- Publication
EJNMMI Research, 2019, Vol 9, Issue 1, pN.PAG
- ISSN
2191-219X
- Publication type
Article
- DOI
10.1186/s13550-019-0521-x